Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 2
2011 10
2012 15
2013 16
2014 3
2015 3
2016 2
2019 2
2020 1
2022 1
2023 1
2024 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549. N Engl J Med. 2020. PMID: 32101663 Clinical Trial.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651. N Engl J Med. 2022. PMID: 35139274 Clinical Trial.
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kümmel S, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Im SA, Untch M, Fasching PA, Mouret-Reynier MA, Foukakis T, Ferreira M, Cardoso F, Zhou X, Karantza V, Tryfonidis K, Aktan G, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. N Engl J Med. 2024 Nov 28;391(21):1981-1991. doi: 10.1056/NEJMoa2409932. Epub 2024 Sep 15. N Engl J Med. 2024. PMID: 39282906 Clinical Trial.
Patellar metastasis of melanoma.
Tas F, Keskin S. Tas F, et al. Among authors: keskin s. Indian J Med Res. 2013 Sep;138(3):370. Indian J Med Res. 2013. PMID: 24135186 Free PMC article. Review. No abstract available.
A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy.
Kilickap S, Ozturk A, Karadurmus N, Korkmaz T, Yumuk PF, Cicin I, Paydas S, Cilbir E, Sakalar T, Uysal M, Yesil Cinkir H, Uskent N, Demir N, Sakin A, Dursun OU, Aver B, Turhal NS, Keskin S, Tural D, Eralp Y, Bugdayci Basal F, Yasar HA, Sendur MAN, Demirci U, Cubukcu E, Karaagac M, Cakar B, Tatli AM, Yetisyigit T, Urvay S, Gursoy P, Oyan B, Turna ZH, Isikdogan A, Olmez OF, Yazici O, Cabuk D, Seker MM, Unal OU, Meydan N, Okutur SK, Tunali D, Erman M; Lung Sub-Group Study of the Turkish Oncology Group. Kilickap S, et al. Among authors: keskin s. Medicine (Baltimore). 2024 May 24;103(21):e37972. doi: 10.1097/MD.0000000000037972. Medicine (Baltimore). 2024. PMID: 38787994 Free PMC article.
53 results